In line with international trends, the Advancing of Australian Pharmacy Practice credential provides a pathway to improved outcomes for patients.
Now available on the PBS, BRIVIACT (brivaracetam) is an add-on therapy for the treatment of partial-onset seizures (POS).
Low-level lead exposure may be responsible for around 30% of premature deaths from cardiovascular disease in the USA each year.
Hospital pharmacists are committed to supporting sustainability.
Fentanyl — alone, or in combination with stimulants — may put substance users at further risk, whether they take it knowingly or not, by causing amnesia.
The product is approved for the treatment of schizophrenia and bipolar I disorder, as well as for use as an add-on treatment for depression in adults.
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.
The Pharmaceutical Benefit Scheme (PBS) medicines in hospitals program enables hospital access to PBS funding in some capacity in most states and territories. Adoption by NSW and the ACT would cement this landmark program.
A cure to diabetes is one step closer, with scientists exploring insulin-secreting skin cells.
A urine test may offer more definitive evidence of GHB, supporting law enforcement.
Researchers testing medical marijuana on epilepsy have found it can adversely interact with antiepileptic drugs.
A day in the life of Jason Seet, an Infectious Diseases/Critical Care Pharmacist at Sir Charles Gairdner Hospital in Perth, WA.
Many clinical trials are finding that aspirin can slow or prevent cancer.
Ketamine is increasingly being used off-label to treat depression, but the long-term effects have not been examined.
$16m invested for the national rollout of real-time prescription monitoring to prevent misuse and loss of life.